Minorities Less Likely to Receive Monoclonal Antibody Tx for COVID-19

Use of monoclonal antibody (mAb) treatment is lower for minority COVID-19 patients. Data from 41 health systems (805,276 patients) showed mean monthly use of mAb treatment was low overall (<4%) but was even lower among Black (2.8%), Asian (2.2%), and Hispanic (1.8%) patients vs. White patients (4%).

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ